Bronchiectasis Hospitalizations: A Deadlier and Costlier Concern Than COPD or Asthma
A recent study reveals a stark contrast in outcomes for patients hospitalized with bronchiectasis compared to those with COPD or asthma. The research, published in ERJ Open Research, highlights the higher mortality rates, longer hospital stays, and increased costs associated with bronchiectasis exacerbations.
The study analyzed hospitalization trends for bronchiectasis, COPD, and asthma from 2017 to 2021 using the National Inpatient Sample (NIS), a comprehensive US database. The findings underscore the need for improved clinical strategies and heightened awareness of bronchiectasis to enhance patient outcomes and alleviate the healthcare burden.
Key Findings:
- Mortality Rates: Patients with bronchiectasis had a crude mortality rate of 5.8%, significantly higher than COPD (5.0%) and asthma (1.5%). After adjusting for comorbidities, the risk of death for bronchiectasis patients was 1.2 times that of COPD patients and 3.0 times that of asthma patients.
- Hospital Length of Stay: Bronchiectasis patients experienced the longest hospital stays, with a median of 5 days, compared to 3 days for asthma patients and 4 days for COPD patients.
- Hospital Costs: The financial burden of bronchiectasis hospitalizations was substantial, with a median cost of $50,393 per hospitalization, surpassing the costs for COPD and asthma.
- Impact of COVID-19: While hospitalizations for COPD and asthma decreased during the pandemic, bronchiectasis hospitalizations remained relatively stable, increasing from 42,374 in 2020 to 45,866 in 2021, approaching pre-pandemic levels.
- Overlapping Conditions: The study also revealed that hospitalizations for bronchiectasis alone were associated with the highest mortality rates, surpassing those with bronchiectasis-COPD or bronchiectasis-asthma overlap.
The researchers emphasize the importance of targeted management strategies and increased awareness of bronchiectasis to address these concerning outcomes and reduce the healthcare burden. The study's findings highlight the need for further research and clinical interventions to improve the lives of patients with bronchiectasis.
